- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01090154
Study of Cimzia for the Treatment of Ulcerative Colitis (UC CIMZIA)
December 10, 2021 updated by: Scott Lee, University of Washington
Certolizumab Pegol for the Treatment of Moderate to Severe Ulcerative Colitis: An Open Label Study
The purpose of this study is to determine if Cimzia (certolizumab pegol) is an effective treatment for patients with Ulcerative colitis.
Study Overview
Detailed Description
Ulcerative colitis (UC) is a chronic inflammatory bowel disease which often results in significant morbidity as well as impairment in quality of life.
Cimzia (certolizumab pegol), an inhibitor of tumor necrosis factor-alpha, is an effective treatment for Crohn's disease, a similar inflammatory bowel disease.
The aims of this study are to determine if Cimzia is effective for both the induction and maintenance of response/remission for the patients with moderate to severe Ulcerative colitis.
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Adults aged 18-75 years
- Established diagnosis of UC (by routine clinical, radiologic, endoscopic, and histologic criteria) of at least 3 months duration
- Moderate to severe active disease, defined by Mayo score > 6 with endoscopic subscore > 2
- Ability to understand the study protocol and treatments, willingness to comply with all study requirements, and ability to provide informed consent
- No history of prior tuberculosis (TB), no signs or symptoms of active TB, and negative Quantiferon gold test or PPD and chest X-ray showing no active or latent TB at screening or within the 6 months prior to the screening visit.
- Screening blood tests must meet the following criteria: white blood cell count > 3000/µL (with neutrophils > 1500/µL and lymphocytes > 500/µL), hemoglobin > 8 g/dL, platelet count > 100,000/µL, liver function tests < 3 times the upper limit of normal, serum creatitine < 1.5 mg/dL
- Screening stool sample negative for Clostriduim difficile, ova & parasites, and aerobic pathogens, including Aeromonas, Plesiomonas, Salmonella, Shigella, Yersinia, Campylobacter, and E. coli spp.
Medication use must meet the following criteria:
- Rectally administered topical 5-aminosalicylates (5-ASAs)/corticosteroids: must be discontinued by 1 month prior to baseline; not allowed during the study
- Oral 5-ASAs: allowed if at stable dose for at least 2 weeks prior to baseline; can remain on this stable dose during the study
- Antibiotics for UC: must be discontinued by 1 month prior to baseline; not allowed during the study
- Antidiarrheals: must be discontinued by 2 weeks prior to baseline; not allowed during the study
- Corticosteroids: allowed if at Prednisone dose equivalent of 20 mg/d or less, stable for 2 weeks prior to baseline (dose/taper during study discussed below); budesonide is allowed at a dose less than or equal to 9 mg/day if at stable dose for 2 weeks prior to baseline
- 6-Mercaptopurine (6MP)/Azathioprine/Methotrexate: allowed if on for at least 8 weeks, at stable dose for at least 4 weeks prior to baseline; can remain on this stable dose during the study
- Anti-TNF therapy: Patients must be naive to CZP. Patients may have had prior exposure to anti-TNF therapy (e.g., infliximab, adalimumab, golimumab), however patients who are primary non-responders to more than one anti-TNF medication are excluded. Patients must have been off their prior anti-TNF medication for at least 8 weeks prior to baseline.
- Integrin inhibitor therapy: Patients may have had prior exposure to integrin inhibitor therapy (e.g., vedolizumab). Patients must have been off of integrin inhibitor therapy for at least 8 weeks prior to baseline.
- Cyclosporine: patients previously receiving Cyclosporine for UC must have been off their prior Cyclosporine therapy for at least 4 weeks prior to baseline.
- Any other medications for the treatment of Ulcerative colitis or investigational medications: must be discontinued at least 1 month or 5 half-lives (whichever is longer) before baseline; not allowed during the study
- Female subjects of childbearing potential must agree to practice an effective method of birth control during the study and for 12 weeks after the last dose of study drug. Acceptable methods include: oral contraceptives, transdermal contraceptives, injectable contraceptives, implants, intrauterine devices, barrier methods with spermicide, or surgical sterility.
Exclusion Criteria
- Diagnosis of Crohn's disease or indeterminate colitis, or clinical findings suggestive of Crohn's disease
- Fulminant disease, toxic megacolon, or anticipated imminent colectomy
- Presence of ileal pouch or ostomy
- Pregnancy, desire to become pregnant during the following 18 months, or breast feeding
- Surgery of any kind within 2 months of screening or anticipated surgery of any kind during the study
- Anticipated imminent hospitalization for any medical conditions
- Active ongoing infection of any kind
- Current use of total parenteral nutrition
History of:
- Congestive heart failure or significant coronary artery disease (including myocardial infarction, percutaneous coronary intervention, or coronary artery bypass within 6 months of screening)
- Cancer
- Colonic dysplasia (except sporadic adenomas). Also, patients found to have colonic dysplasia at any time during the study will be withdrawn from the study.
- HIV, chronic or active hepatitis B or C, or patients considered at high risk for these infections (obtained by history/detailed medical chart review except for hepatitis B, which will be tested for with blood sample)
- Prior opportunistic infection within 6 months of screening or prior opportunistic infection while on other anti-TNF therapy
- Hepatic disease (cirrhosis, chronic active hepatitis, or LFT abnormalities as above)
- Renal insufficiency (see above)
- Clinically important pulmonary disease (as determined subjectively)
- Demyelinating disease
- Organ transplantation, including bone marrow (except corneal)
- Lymphoproliferative disorder
SAMPLE SIZE CALCULATION
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cimzia
Treatment with open label Cimzia (certolizumab pegol)
|
Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the proportion of patients achieving clinical response determined by patient reported symptoms and investigator's assessment of mucosal healing via endoscopy measured by Total Mayo Score at Week 14 compared to Week 0.
Time Frame: Week 14
|
Clinical response is defined as a decrease in the Total Mayo Score of at least 3 points by Week 14 compared to Week 0.
|
Week 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the proportion of patients achieving clinical remission determined by patient reported symptoms and investigator's assessment of mucosal healing via endoscopy measured by Total Mayo Score at Week 14 compared to Week 0.
Time Frame: Week 14
|
Clinical remission is defined as a total Mayo score of less than or equal to 2 with no individual subscore greater than 1 at Week 14 compared to Week 0.
|
Week 14
|
To determine the proportion of patients achieving clinical response or clinical remission at week 54 per the same criteria as listed above.
Time Frame: Week 54
|
Week 54
|
|
To determine the proportion of patients achieving mucosal healing at weeks 14 and 54 defined as a Mayo endoscopic subscore less than 2.
Time Frame: Week 14/54
|
Week 14/54
|
|
To determine the corticosteroid-sparing effects of certolizumab pegol over a years treatment time.
Time Frame: Week 54
|
To determine if patients are able to remain off steroids and maintain response or remission with certolizumab pegol alone and not necessitate concomitant treatment with steroids.
|
Week 54
|
To determine the colectomy rate between week 0 and week 54
Time Frame: Week 54
|
Week 54
|
|
To determine the change in mean or median total or partial Mayo score between week 0 and week 54
Time Frame: Week 54
|
Week 54
|
|
To determine the change in mean or median serum CRP levels between week 0 and week 54
Time Frame: Week 54
|
Week 54
|
|
To determine the change in mean or median IBDQ or SIBDQ scores between week 0 and week 54
Time Frame: Week 54
|
Week 54
|
|
To determine all adverse events, serious adverse events, opportunistic infections, and injection site reactions between week 0 and week 64
Time Frame: Week 64
|
Week 64
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Scott D Lee, MD, University of Washington
- Principal Investigator: Mark T Osterman, MD, University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2010
Primary Completion (Actual)
December 10, 2021
Study Completion (Actual)
December 10, 2021
Study Registration Dates
First Submitted
March 15, 2010
First Submitted That Met QC Criteria
March 17, 2010
First Posted (Estimate)
March 19, 2010
Study Record Updates
Last Update Posted (Actual)
December 14, 2021
Last Update Submitted That Met QC Criteria
December 10, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Gastroenteritis
- Colonic Diseases
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Ulcer
- Colitis
- Colitis, Ulcerative
- Physiological Effects of Drugs
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Certolizumab Pegol
Other Study ID Numbers
- 37823
- CZP-UC-001 (Other Identifier: Protocol Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Immune PharmaceuticalsUnknownUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
Clinical Trials on Cimzia
-
University Hospital, GhentUCB Pharma SACompletedRheumatoid Arthritis | Axial and Peripheral SpondyloarthritisBelgium
-
UCB Biopharma S.P.R.L.CompletedModerate and Severe Active Rheumatoid Arthritis | Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Moderately to Severely Active Crohn's DiseaseUnited States
-
Robert Flavell, MD, PhDSuspended
-
UCB PharmaCompletedRheumatoid ArthritisPoland, Germany, Austria, France, Italy
-
UCB PharmaCompletedOpen Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid ArthritisRheumatoid ArthritisUnited States, United Kingdom, Belgium, Germany, Austria, Ireland, Czechia
-
Shafran Gastroenterology CenterUCB PharmaUnknownCrohn's DiseaseUnited States
-
University of Erlangen-Nürnberg Medical SchoolCompletedRheumatoid ArthritisGermany, Portugal, Serbia
-
UCB CelltechTerminatedCrohn's DiseaseUnited States, Canada, New Zealand, Australia
-
UCB BIOSCIENCES, Inc.Completed
-
UCB Biopharma SRLCompletedAxial Spondyloarthritis (axSpA) | Anterior Uveitis (AU)Czechia, Germany, Netherlands, Poland, Spain